.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Molecular Targets on the Horizon in Non–Small Cell Lung Cancer

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive.

EP. 1: Dr. Gandara on Developments in HER2-Targeted Therapies in NSCLC

July 23rd 2021

David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.

EP. 2: Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer

July 23rd 2021

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

EP. 3: Dr. Santos on the Potential Role for CEACAM5- and KEAP1-Targeted Therapies in NSCLC

August 17th 2021

Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.

EP. 4: Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer

August 17th 2021

Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.

EP. 5: Dr. Skoulidis on the Rationale to Target TROP2 in Lung Cancer

August 17th 2021

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.